Clinical Trial Update: A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma [Phase 1]

View source ↗

Summary

A Phase I trial evaluating lapatinib plus ixabepilone as second-line therapy for patients with HER-2 overexpressing recurrent or persistent endometrial carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Uterine Carcinosarcoma

Drugs mentioned

• Ixempra (ixabepilone) (ixabepilone)
• Tykerb (lapatinib) (lapatinib)

Snippet

Sponsor: Hung-Hsueh Chou | Conditions: Recurrent Endometrial Cancer | Phase 1 | Status: UNKNOWN